Cell-Based Assay System for Drug Screening

A new cell-based assay system is designed specifically for cell-based secondary screening and pharmacology profiling of potential new drug leads.

More than 80% of all drug screening relies on cell-based assays to provide vital information on compounds with therapeutic potential. The new system is the first automated system dedicated to high-content profiling of compounds targeting G-protein coupled receptors (GPCRs) and ion channels. Positive verification of such compounds is automatically followed by dose-response curves and retrieval of critical pharmacology parameters that provide useful information on potency, mechanism of action, specificity, and efficacy.

Called Procel, the assay system was developed by Biacore International AB (Uppsala, Sweden) and complements the company's Biacore S51, launched earlier for lead characterization and preclinical applications. Biacore says the two platforms offer a fully integrated solution of both cellular and molecular based assays designed to accelerate the optimization of quality lead compounds for drug development.


”Procel's complementary position alongside Biacore S51 allows critical decisions to be made earlier in the drug discovery process. We therefore predict sales synergies in markets where we have already been successful with complementary technologies,” said Julian Abery, vice president and head of the Pharmaceutical & Biotechnology business unit at Biacore.




Related Links:
Biacore